Adage Capital Partners
XFOR icon

Adage Capital Partners’s X4 Pharmaceuticals XFOR Stock Holding History

Adage Capital Partners’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-142,544
Closed -$2.86M – 969
2024
Q3 		$2.86M Hold
142,544
– – 0.01% 762
2024
Q2 		$2.48M Hold
142,544
– – ﹤0.01% 769
2024
Q1 		$5.94M Hold
142,544
– – 0.01% 677
2023
Q4 		$3.59M Hold
142,544
– – 0.01% 709
2023
Q3 		$4.66M Hold
142,544
– – 0.01% 673
2023
Q2 		$8.3M Buy
+142,544
New +$7.33M 0.02% 600

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners's XFOR Position: Q4 2024 in Review

Adage Capital Partners sold out of X4 Pharmaceuticals (XFOR) in Q4 2024, closing a stake of 142,544 shares — an estimated $2.86M sold.

Adage Capital Partners first reported a position in XFOR in Q2 2023 and held it in 6 quarters. The position peaked at $8.3M in Q2 2023. 89 funds tracked by Wall St. Rank hold XFOR as of Q4 2024.

  • Adage Capital Partners reported no remaining X4 Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Adage Capital Partners sold 142,544 X4 Pharmaceuticals shares in Q4 2024, an estimated $2.86M.
  • Adage Capital Partners first reported a position in X4 Pharmaceuticals in Q2 2023 and held it in 6 quarters.
  • Adage Capital Partners's X4 Pharmaceuticals position peaked at $8.3M in Q2 2023.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2024.

Based on Adage Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.